NCT00783237

Onset of Effect of Mometasone Nasal Spray in Induced Allergic Rhinitis (Study P03431)

Onset of Action of Mometasone Furoate Nasal Spray vs. Placebo in Induced Allergic Rhinitis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 340 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

This was a single-dose study to determine the time it takes for mometasone furoate nasal spray to go in effect, after a single dose of 2 sprays per nostril. Patients who are eligible were exposed to ragweed pollen for 3 hours on one or two occasions. Patients who experienced adequate symptoms during the pollen exposure phase came back for a Treatment Phase visit. During the Treatment Phase visit, patients were exposed to ragweed pollen for 2 hours and then received either mometasone or placebo nasal spray. Symptom evaluations began on the patients every hour for the next 11 hours.

Conditions

• Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	Mometasone	Mometasone Furoate Nasal Spray, single dose of 200 mcg (2 sprays per nostril)
DRUG	Placebo	Placebo nasal spray, single dose of 2 sprays per nostril

Timeline

• Start date: 2003-12-01
• Primary completion: 2004-02-21
• Completion: 2004-02-21
• First posted: 2008-10-31
• Last updated: 2024-08-15